For epidermal growth factor (EGFR) mutated non-small cell lung carcinoma (NSCLC) multiple EGFR tyrosine kinase inhibitors (TKIs) are approved. ERBB2 alteration (mutation and/or amplification) is associated with poor survival in NSCLS patients and is commonly reported as a resistance mechanism to EGFR TKIs.
Investigate the prevalence of ERBB2 alteration with or without EGFR as a co-mutation in NSCLC. Describe type of ERBB2 mutation and EGFR mutation when both are present as co-mutation.
A minority of EGFR mutated NSCLC patients had ERBB2 alterations. ▪ In ERBB2 and EGFR co-mutated patients, exon 21 mutations for EGFR and exon 8 mutations for ERBB2 were common. ▪ Forty percent of patients who had exon 8 ERBB2 mutation had EGFR as a co-mutation.Download Publication